Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 55Recurrence 6Lymphoma, Mantle-Cell 5Leukemia, Myeloid, Acute 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 3Lymphoma 3Plasmacytoma 2Neoplasms 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1

Interventions

pembrolizumab 36Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13Carboplatin 10enfortumab vedotin 9durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × ixazomib × Clear all
NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
57 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡